Loading…
UTI - Pharma & Healthcare Fund
Disclosed for 41 months, Jan 2014 to Jun 2017. This scheme is no longer reporting.
Portfolio value
₹315 Cr
up ₹7.6 Cr vs Mar 2016
- Stocks held
- 25
- down 1 vs Mar 2016
- Top 10 weight
- 72.1%
- of the portfolio in its ten largest
- Cash & debt
UTI - Pharma & Healthcare Fund is an active equity fund in the Sectoral / Thematic category from UTI Mutual Fund. In April 2016 it disclosed 25 stocks worth ₹315 Cr, up ₹7.6 Cr from Mar 2016. Its largest positions were Sun Pharmaceutical Industries Limited (22.2%), Dr. Reddy's Laboratories Limited (11.5%), Lupin Limited (9.9%); the ten largest together made up 72.1% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 86.7% of its equity. Cash and debt stood at 7.6%. Compared with Mar 2016 the fund entered 0 new stocks and exited 1.
Against 230 other Sectoral / Thematic funds
Concentration
94%
Top-10 weight is higher than 94% of peers
Breadth
8%
Holds more stocks than 8% of peers
Cash
87%
Holds more cash than 87% of peers
What these mean: concentration · cash
Holdings in April 2016
Download CSVEvery line the fund disclosed, with the change against Mar 2016. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 22.24% | down 0.80 pts | ₹70 Cr | down ₹75 L | Trimmed |
| Dr. Reddy's Laboratories Limited | 11.45% | down 0.08 pts | ₹36 Cr | up ₹62 L | Added |
| Lupin Limited | 9.93% | up 0.56 pts | ₹31.2 Cr | up ₹2.5 Cr | Added |
| Cipla Limited | 8.64% | up 0.20 pts | ₹27.2 Cr | up ₹1.3 Cr | Added |
| Cash, TREPS & receivables | 7.62% | down 0.30 pts | ₹24 Cr | down ₹35 L | Trimmed |
| Divi's Laboratories Limited | 4.33% | up 0.16 pts | ₹13.6 Cr | up ₹83 L | Added |
| Aurobindo Pharma Limited | 3.66% | down 0.02 pts | ₹11.5 Cr | up ₹23 L | Added |
| Biocon Limited | 3.38% | up 0.52 pts | ₹10.6 Cr | up ₹1.9 Cr | Added |
| Piramal Enterprises Limited | 3.30% | up 0.35 pts | ₹10.4 Cr | up ₹1.3 Cr | Added |
| Alkem Laboratories Limited | 2.79% | down 0.47 pts | ₹8.8 Cr | down ₹1.2 Cr | Trimmed |
| Narayana Hrudayalaya Limited | 2.38% | up 0.03 pts | ₹7.5 Cr | up ₹27 L | Added |
| Sun Pharma Advanced Research Company Limited | 2.32% | up 0.14 pts | ₹7.3 Cr | up ₹60 L | Added |
| IPCA Laboratories Limited | 2.31% | down 0.46 pts | ₹7.3 Cr | down ₹1.2 Cr | Trimmed |
| Zydus Lifesciences Limited | 2.24% | up 0.02 pts | ₹7 Cr | up ₹23 L | Added |
| Strides Pharma Science Limited | 1.91% | down 0.05 pts | ₹6 Cr | down ₹2 L | Held |
| Sanofi India Limited | 1.63% | up 0.11 pts | ₹5.1 Cr | up ₹46 L | Added |
| Pfizer Limited | 1.60% | down 0.09 pts | ₹5 Cr | down ₹16 L | Trimmed |
| GlaxoSmithKline Pharmaceuticals Limited | 1.51% | down 0.07 pts | ₹4.8 Cr | down ₹11 L | Trimmed |
| Unichem Laboratories Limited | 1.37% | up 0.11 pts | ₹4.3 Cr | up ₹44 L | Added |
| Syngene International Limited | 1.23% | down 0.02 pts | ₹3.9 Cr | up ₹4 L | Added |
| Indraprastha Medical Corporation Limited | 1.10% | up 0.04 pts | ₹3.5 Cr | up ₹21 L | Added |
| Natco Pharma Limited | 0.94% | up 0.13 pts | ₹3 Cr | up ₹47 L | Added |
| DISHMAN PHARMACEUTICALS & CHEMICALS LTD. | 0.65% | down 0.01 pts | ₹2.1 Cr | up ₹3 L | Added |
| Torrent Pharmaceuticals Limited | 0.65% | up 0.03 pts | ₹2 Cr | up ₹13 L | Added |
| Shilpa Medicare Limited | 0.45% | up 0.03 pts | ₹1.4 Cr | up ₹14 L | Added |
| Indoco Remedies Limited | 0.38% | down 0.04 pts | ₹1.2 Cr | down ₹11 L | Trimmed |
What changed, Mar 2016 to Apr 2016
New New positions (0)
None.
Exited Exited (1)
- EQ-PP SUN PHARMA ADVANCED RESEARCH CO LTD.was <0.1% · ₹4 L
Added Biggest additions
- Lupin Limitedup ₹2.5 Cr (+0.56% pts)
- Biocon Limitedup ₹1.9 Cr (+0.52% pts)
- Piramal Enterprises Limitedup ₹1.3 Cr (+0.35% pts)
- Cipla Limitedup ₹1.3 Cr (+0.20% pts)
- Divi's Laboratories Limited
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Mar 2016, the weight rose most in Finance (+0.4 pts), and fell most in Pharmaceuticals & Biotechnology (−0.4 pts).
- Finance3.2% → 3.6%+0.4 pts
- Pharmaceuticals & Biotechnology87.1% → 86.7%−0.4 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Apr 2015 | Oct 2015 | Jan 2016 | Mar 2016 | Apr 2016 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 92.3% | 89.6% | 86.7% | 87.1% | 86.7% |
| Healthcare Services | — | 2.4% | 5.5% | 5.0% | 5.1% |
| Pharmaceuticals | 6.5% | 5.2% | 4.8% | 4.7% | 4.7% |
| Finance | 1.1% | 2.7% | 3.0% | 3.2% | 3.6% |
Allocation in Apr 2016change vs Mar 2016
- Pharmaceuticals & Biotechnology (17)86.7%▼ 0.4 pts
- Healthcare Services (3)5.1%
- Pharmaceuticals (4)4.7%
- Finance (1)3.6%▲ 0.4 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Apr 2016
7.6%
▼ 0.3 pts vs Mar 2016
- Cash alone
- 7.6%
- cash and net receivables
- A year earlier
- 9.3%
- Apr 2015 · now ▼ 1.7 pts
- Last 12 months
- 5.9% – 12.6%
- lowest to highest · record 12.6% in Nov 2015
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.